The China Pharmaceutical Market to 2030
Every news service globally is focused on COVID-19 ("Coronavirus") and how it will affect the global population, but what of the China health system itself?
By: Bharat Book Bureau
What will drive and restrain the Chinese health markets?
- Increase in Non-Communicable Disease (NCD)
- Elderly population
- Expanding Middle Class
- Governmental Policy / Trade War
- Industry Harmonization with Global Markets
Request a free sample copy China Pharmaceutical Market Report @
The Chinese pharmaceutical sector is set for substantial growth across the next decade as an increasing middle class, which has greater access to healthcare, is set to drive the domestic market significantly. A growing population, which is tilted towards the middle aged and elderly, is another factor that will boost Chinese healthcare and pharmaceutical markets.
China is the largest supplier of raw materials to that produce high-priced, non-generic drugs produced by the US, with an ongoing Trade war Chinese pharmaceuticals face tariffs; this is likely to strengthen the domestic (Chinese) pharmaceutical market in the short to mid-term.
China became a member of the International Council for Harmonization in 2017 and accepted declarations in clinical trials/ approvals by the US FDA and the EMA, shortening clinical trial authorization processes significantly in China.
This report is the single tool to equip you with the latest trends in the Chinese pharmaceutical market. This report will arm you with all you and your company require to develop, price, launch and market a product in China, or compete with a Chinese product launched in your market.
With over 100 pages, and over 60+ charts, tables, figures and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.
Browse our full report with Table of Content : https://www.bharatbook.com/
Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773